SB 061

Drug Profile

SB 061

Alternative Names: SB-061

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator SYMIC Biomedical
  • Developer Nordic Bioscience; SYMIC Biomedical
  • Class Proteoglycans
  • Mechanism of Action Proteoglycan replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Osteoarthritis

Most Recent Events

  • 18 May 2017 Efficacy and safety data from the phase I/IIa MODIFY-OA trial in Osteoarthritis released by Symic Bio
  • 18 May 2017 Symic Bio plans a phase II trial in Osteoarthritis in 2017
  • 10 Nov 2016 Symic Bio completes enrolment in its phase I/II trial for Osteoarthritis in Estonia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top